Dupont Capital Management’s Pacific Biosciences PACB Stock Holding History

Dupont Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-19,808	Closed	-$115K	–	1498
2022 Q3	$115K	Buy	+19,808	New	+$114K	0.01%	990
2021 Q3	–	Sell	-17,581	Closed	-$615K	–	1798
2021 Q2	$615K	Buy	+17,581	New	+$511K	0.01%	872
2020 Q4	–	Sell	-96,079	Closed	-$948K	–	1383
2020 Q3	$948K	Sell	96,079 -20,228	-17%	-$116K	0.02%	535
2020 Q2	$401K	Buy	116,307 +17,090	+17%	+$58.2K	0.01%	867
2020 Q1	$304K	Sell	99,217 -146,999	-60%	-$602K	0.01%	858
2019 Q4	$1.27M	Buy	246,216 +76,360	+45%	+$388K	0.03%	495
2019 Q3	$876K	Sell	169,856 -40,307	-19%	-$225K	0.02%	575
2019 Q2	$1.27M	Buy	210,163 +125,760	+149%	+$882K	0.03%	477
2019 Q1	$610K	Buy	+84,403	New	+$610K	0.01%	700

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dupont Capital Management's PACB Position: Q4 2022 in Review

Dupont Capital Management sold out of Pacific Biosciences (PACB) in Q4 2022, closing a stake of 19,808 shares — an estimated $115K sold.

Dupont Capital Management first reported a position in PACB in Q1 2019 and held it in 9 quarters. The position peaked at $1.27M in Q2 2019. 236 funds tracked by Wall St. Rank hold PACB as of Q4 2022.

Dupont Capital Management reported no remaining Pacific Biosciences position as of Q4 2022 after selling out during the quarter.
Dupont Capital Management sold 19,808 Pacific Biosciences shares in Q4 2022, an estimated $115K.
Dupont Capital Management first reported a position in Pacific Biosciences in Q1 2019 and held it in 9 quarters.
Dupont Capital Management's Pacific Biosciences position peaked at $1.27M in Q2 2019.
236 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2022.

Based on Dupont Capital Management's 13F filing for Q4 2022, filed 26 Jan 2023.